Smad7 by interfering with Smurf-mediated degradation. Our results identify a mechanism that regulates the acand Smad3), and subsequently, a heteromeric complex with the common-mediator Smad (Co-Smad; Smad4) is tivity of Smad7 and indicate that competition between ubiquitination and acetylation of common lysine resiformed. The Smad complexes then translocate into the nucleus where they, in cooperation with coactivators dues controls the stability of Smad7. and corepressors, act as transcription factors regulating gene expression.
Results

The inhibitory Smads (I-Smads; Smad6 and Smad7) are induced by receptor signaling and act as negative
Smad7 Interacts with p300 regulators of the pathway. Smad7 resides in the nucleus
To analyze if Smad7 is directly associated with compoin unstimulated cells and translocates to the plasma nents of the transcriptional machinery, we performed membrane following receptor activation (Itoh et al., coimmunoprecipitation experiments in transiently transfected 293T cells, using full-length p300 and three different Smad7 constructs. Full-length Smad7 and Smad7⌬N (amino acids 204-402) interacted strongly with p300, the acetyltransferase activity of p300. In order to test this possibility, 293T cells were transfected with Smad7 while Smad7⌬C (amino acids 2-261) failed to do so ( Figure 1A) , indicating that the C-terminal domain of alone or together with p300, CBP, or P/CAF, and the acetylation of Smad7 was monitored by anti-acetyl lySmad7 is required for binding to full-length p300.
To further map the interaction between Smad7 and sine antibodies (Figure 2A ). Although CBP and p300 are homologous and have overlapping functions, p300 p300, we performed GST pull-down experiments using GST-Smad7 together with four in vitro translated p300 induced a robust acetylation of Smad7, whereas CBP and P/CAF failed to acetylate Smad7 ( Figure 2A , lanes fragments (amino acids 2-411, 412-1150, 1151-1673, and 1674-2414). Full-length Smad7 interacted with all 1-4). CBP and P/CAF were able to acetylate p53, both in vivo and in vitro (data not shown), confirming their p300 fragments except the region between amino acids 412-1150 ( Figure 1B) . activity toward other substrates. To investigate whether acetylation of Smad7 is regulated in response to TGF␤ The intrinsic HAT activity of p300 is contained within one of the fragments used in Figure 1B (amino acids signaling, the experiment was also performed in the presence of constitutively active TGF␤ receptor (caALK5); 1151-1673), indicating that Smad7 interacts with the HAT domain of p300. To further map this interaction, coexpression of caALK5 decreased the acetylation of Smad7 by p300 (compare lanes 2 and 6 in Figure 2A ). the HAT domain of p300 was in vitro translated and used in pull-down experiments with various fragments Smad7 was acetylated by endogenous acetyltransferases when expressed in HaCaT cells ( Figure 2B ). Interof Smad7. Both full-length and the N-terminal fragment of Smad7 interacted with the HAT domain of p300, estingly, RNAi-mediated inactivation of endogenous p300 blocked this acetylation, demonstrating that p300 whereas the C-terminal part of Smad7 was unable to interact with this domain of p300 ( Figure 1C ). This sugis required for the acetylation of Smad7 in vivo.
To map the acetylated lysines in Smad7, we pergested that the N terminus of Smad7 could be a target for the acetyltransferase activity of p300.
formed in vitro acetylation assays using p300 and GSTSmad7, either full-length, Smad7⌬N, or Smad7⌬C. FullTo determine whether endogenous Smad7 and p300 form a complex in vivo, we used anti-Smad7 antibodies length Smad7 and Smad7⌬C were acetylated by p300, while p300 failed to acetylate Smad7⌬N, indicating that to immunoprecipitate Smad7 from HaCaT cell lysates. p300 was detected in the Smad7 immunoprecipitates, the acetylated lysine residues reside in the N terminus of Smad7 ( Figure 3A ). Smad7⌬C interacts poorly with indicating that Smad7 and p300 interact in vivo ( Figure  1D ). In contrast, no p300 was detected when an unrep300 ( Figure 1A) , and the fact that it is acetylated as efficiently as full-length Smad7 could indicate that the lated antibody was used in the immunoprecipitation. acetylated residues are not fully accessible in full-length Smad7 in vitro. In order to identify the acetylated resiThe N Terminus of Smad7 Is Acetylated by p300 The fact that Smad7 interacted with the HAT domain of dues, we analyzed tryptic fragments of in vitro acetylated GST-Smad7 by mass spectrometry. Compared p300 suggested that Smad7 could be a substrate for seen. This lack of acetylation could not be explained by effects on the interaction between Smad7 and p300, respectively), suggesting that these residues are targets for p300-mediated acetylation in vitro.
since Smad7(K64/70A) still interacted with full-length Figure 5A ). The expression of Smad7(K64A) was higher than that of wild-type Smad7 ( Figure 5A , 4E).
To confirm that Smad7 is acetylated in vivo, endogelanes 1 and 3), and only a weak induction in response to p300 could be observed (lanes 3 and 4). The levels nous Smad7 was immunoprecipitated from HaCaT cell lysates. The anti-Smad7 antibody immunoprecipitated of Smad7(K70A) and the double mutant (K64/70A) were very high in the absence of p300, and no significant acetylated Smad7, while an unrelated antibody was unable to do so ( Figure 4F) . increase was observed in response to p300 expression ( Figure 5A, lanes 5-8) . These results indicate that acetylation by p300 or mutation of K64 and K70 increases Acetylation of Smad7 Inhibits Its Degradation Theoretically, acetylation of specific lysines could inthe stability of Smad7. In support of this notion, the p300-mediated stabilization of Smad7 was dependent crease the stability of a protein, since acetylation would prevent ubiquitination of the same lysine residues. In on the acetyltransferase activity of p300, since an acetyltransferase-deficient mutant form of p300 (p300-DY) order to determine if p300 could affect the expression of Smad7, 293T cells were transfected with Smad7, either was unable to stabilize Smad7 ( Figure 5B ). As shown above, p300-DY is able to interact with Smad7 ( Figure  5C ), while all three lysine mutants were resistant to the effects of caALK5 ( Figure 5C, lanes 3-8) . To determine 4E), demonstrating that the interaction between Smad7 and p300 is not sufficient to stabilize Smad7. if p300-mediated acetylation of these lysine residues is able to protect Smad7 from caALK5-mediated degradaTo determine if K64 and K70 are involved in regulating the stability of Smad7 in response to TGF␤ signaling, tion, the experiment described in Figure 5C was repeated in the absence or presence of cotransfected wild-type Smad7 and the different lysine mutants were expressed in 293T cells in the absence or presence p300 ( Figure 5D ). Again, cotransfection of caALK5 decreased the levels of Smad7 in the absence of p300 of constitutively active TGF␤ type I receptor (caALK5). Expression of caALK5 drastically reduced the amounts (compare lanes 1 and 2 in Figure 5D ). However, the enhanced level of Smad7 in the presence of p300 was of wild-type Smad7 (compare lanes 1 and 2 in Figure not reduced by caALK5 ( Figure 5D, lanes 3 and 4) . The indicating that this mutant interferes with p300-mediated acetylation of Smad7 in a dominant-negative manexpression of Smad7(K64A) was higher in the absence of p300 compared to wild-type Smad7, and coexpresner. The dominant-negative p300-DY decreased the expression of Smad7 when the two proteins were coexsion of caALK5 or p300 had no major effects on the expression of this mutant ( Figure 5D, lanes 5-8) . Transpressed in HeLa cells ( Figure 7B ). Interestingly, this effect was dependent on the acetylated lysine residues fected Smad7 was degraded in response to TGF␤ treatment ( Figure 5E, lanes 1 and 2) . Interestingly, expression of p300 blocked TGF␤-dependent degradation of Smad7, and this effect was dependent on the acetyltransferase activity of p300, since the acetyltransferasedeficient p300-DY was unable to stabilize Smad7 ( Figure  5E, lanes 3-6) .
Our results suggest that acetylation of Smad7 enhances its expression, potentially by interfering with the ubiquitin-proteasome pathway. To test this hypothesis, we used GST-Smad7, either wild-type or K64/70A, in a reconstituted in vitro ubiquitination assay ( Figure 5F ). Wild-type Smad7 was ubiquitinated in the presence of rabbit reticulocyte lysate, while a similar amount of Smad7(K64/70A) was significantly less ubiquitinated (compare lanes 2 and 4 in Figure 5F ). To determine if p300-mediated acetylation is able to affect the ubiquitination of Smad7, the experiment was repeated with acetylated and nonacetylated GST-Smad7 ( Figure 5F , lanes 5-10). Interestingly, acetylation of wild-type Smad7 prevented its ubiquitination (compare lanes 6 and 7 in Figure 5F ), while no such effect was seen with Smad7(K64/70A) ( Figure 5F, lanes 9 and 10) . These results suggest that K64 and K70 are targeted by ubiquitination and that p300-mediated acetylation of these residues prevents this process.
The results presented in Figure 5 demonstrate that p300 is able to enhance the expression of Smad7, espe- expressing a HAT-deficient version of p300 (p300-DY), in Smad7, since the K64/70A mutant was insensitive to the destabilizing activity of p300-DY. These results confirm that p300 is required for the acetylation of Smad7 in vivo and indicate that Smad7 is destabilized and degraded when the activity of this acetyltransferase is compromised in cells.
Acetylation Protects Smad7 against Smurf-Mediated Degradation
Smad7 interacts with the ubiquitin ligases Smurf1 and Smurf2, and this interaction furthers the degradation of Smad7. To address the question whether K64 and K70 are involved in Smurf-mediated degradation of Smad7, wild-type and mutant Smad7 were expressed in the absence or presence of Smurf1 ( Figure 8A ). The levels of Smad7 were decreased in response to Smurf1 expression (compare lanes 1 and 2 in Figure 8A ). In contrast, Smad7(K64A), Smad7(K70A), and the double mutant were protected against Smurf-dependent decreases in expression ( Figure 8A, lanes 3-8) , although all mutants tested still interacted with Smurf1 (data not shown). To investigate if p300 is able to protect Smad7 from Smurfmediated degradation, the experiment described in Figure 8A was repeated in the absence or presence of cotransfected p300 ( Figure 8B) . Again, cotransfection of Smurf1 decreased the levels of Smad7 in the absence of p300. In the presence of cotransfected p300, Smurf1 was unable to reduce the levels of Smad7 (compare lanes 3 and 4 in Figure 8B ). Transfected Smad7 was ubiquitinated in response to Smurf1 expression in 293T cells ( Figure 8C) . Interestingly, the Smurf-mediated polyubiquitination of Smad7 was blocked when K64 and K70 were mutated. Taken together with the results presented in Figures 5-7 , our results suggest that K64 and K70 in Smad7 are targeted by Smurf-mediated ubiquitination and that acetylation prevents this process.
Discussion
Here we present evidence that Smad7 interacts with the transcriptional coactivator p300, resulting in acetylation N-terminal domains of p300. Acetylation of Smad7 occurs at the N terminus of the protein, both in vitro and in vivo (Figures 2 and 3 , 2000) . However, the stabiliand P/CAF were unable to acetylate Smad7 in vivo. We were able to reproduce the specificity in acetylation zation was not linked to individual lysine residues in p53, and it is unclear if acetylation of p53 is the only using metabolic labeling of cells with [ The acetylation of Smad7 was significantly decreased Members of the Smurf family of E3 ubiquitin ligases interact with Smads, including Smad7. In the case of following ectopical expression of constitutively active ALK5, indicating that the acetylation of Smad7 is negaSmad7, translocation of the Smad7-Smurf complex from the nucleus to the plasma membrane induces ubiquititively regulated by TGF␤ signaling (Figure 2A) . The interaction between R-and Co-Smads and p300/CBP is ennation and degradation of the TGF␤ receptors. At the plasma membrane, Smad7 is ubiquitinated and dehanced following TGF␤ treatment, and it is possible that the interaction between Smad7 and p300 is disrupted graded, while the nuclear Smad7-Smurf complex is stable (Kavsak et al., 2000) . Interestingly, we found that following activation of the TGF␤ pathway, since Smad7 is translocated out of the nucleus following activation Smurf-mediated poly-ubiquitination of Smad7 was blocked when K64 and K70 were mutated ( Figure 8C ). of the TGF␤ pathway.
Using a combination of in vitro acetylation assays One possibility is that mutation or acetylation of K64 and K70 affects the localization of Smad7 and, thereby, followed by mass spectrometry analyses and mutations of specific Smad7 lysines in vivo, we could map the its stability. However, we were unable to detect any effects on the localization of Smad7 in response to mutaacetylated residues in Smad7 to K64 and K70 in the N terminus of the protein (Figures 3 and 4) . One of these tion of the acetylated lysine residues or as a result of coexpression of p300 (see Supplemental Figure S1 at lysine residues, K64, conforms to the consensus site for acetylation, i.e., a lysine preceded by a glycine or a http://www.molecule.org/cgi/content/full/10/3/483/ DC1). Rather, our results suggest that p300-mediated serine residue. Both sites were also acetylated in vivo, with K64 being the major acceptor site. Interestingly, acetylation of Smad7 protects it against premature Smurf-mediated degradation while in the nucleus. In the acetylation of Smad7, and in particular K70, was greatly enhanced following treatment with the deacetysupport of this model, we found that both the acetylation and stability of Smad7 was decreased in HeLa cells lase inhibitor TSA. This indicates that the acetylation of Smad7 is a dynamic process that is regulated by both expressing an acetyltransferase-deficient p300 mutant ( 
Experimental Procedures
CoA) in the absence or presence of the HAT domain of p300 (50 ng). To avoid unspecific interactions, the samples were incubated Cell Culture with unlabeled acetyl-CoA (final concentration, 1 mM) for an addiAll tissue culture media and antibiotics were from Invitrogen and tional 15 min. SDS sample buffer was added, and the samples were Sigma. Cells were from ATCC and maintained at 37ЊC in DMEM boiled and separated by SDS-PAGE. The gels were dried and anasupplemented with 10% fetal calf serum, sodium pyruvate, noneslyzed by phosphorimage analysis (Fuji). sential amino acids, 50 U/ml penicillin, and 50 g/ml streptomycin, in 5% CO 2 .
In Vitro Ubiquitination Assay GST-Smad7, either wild-type or K64/70A, was used as substrate in TGF␤, Reagents, and Antibodies in vitro ubiquitination reactions in the absence or presence of 5 l TGF␤ was a generous gift from N. Ferrara (Genentech). immunoprecipitated samples were separated by SDS-PAGE. The The corresponding GST-tagged Smad7 constructs were generated gels were dried and analyzed by phosphorimage analysis. by subcloning into pGEX4T-1 (Amersham-Pharmacia Biotech). Smad7 point mutants were generated by site-directed mutagenesis (QuickChange, Stratagene). The various fragments of human p300
Generation of Recombinant Proteins (amino acids 2-411, 412-1150, 1151-1673, and 1674-2414) were and In Vitro Interaction Assays generated by PCR and cloned into HA-pCDNA3. The expression GST-Smad7 fusion proteins and poly-histidine p300-HAT were exvector for HA-tagged constitutively active ALK5 has been described pressed in BL21 E. coli and purified according to standard protocols. previously (Nakao et al., 1997). The expression vectors for p300-HA Proteins were in vitro translated using the T7 TNT kit (Promega) and and Flag-P/CAF were kind gifts from T. Kouzarides (Wellcome/CRC 35 S-labeled methionine and cysteine (Promix), and incubated with Institute, Cambridge, UK). Gal4-tagged p300 and CBP in the GST-fusion proteins prebound to glutathione beads at 4ЊC for 2 hr. pVR1012 vector (Vical) were from N. Perkins (University of Dundee, The samples were washed extensively and resolved by SDS-PAGE. Dundee, UK). The bacterial expression vector for the poly-histidineThe gel was Commassie stained, incubated in enhancer (Amplify, tagged p300 HAT domain (amino acids 1135-1810) was a kind gift Amersham-Pharmacia Biotech), dried, and analyzed by phosphoifrom Y. Nakatani (Dana-Farber Cancer Institute, Boston, MA). The mage analysis. expression vector for Flag-Smurf1 was a kind gift from K. Miyazono (University of Tokyo, Tokyo, Japan). The expression vector for the Mass Spectrometry and Analysis of Acetylated Lysine Residues acetyltransferase-deficient p300 mutant (p300-DY) was a kind gift The Coomassie stained band was excised and treated for in-gel from P. Yao (Duke University, Durham, NC). Transient transfections digestion as described (Hellman, 2000) . The peptide mixture was were performed using the MBS transfection kit (Stratagene). The analyzed by matrix-assisted laser desorption ionization time of flight transfection efficiency was monitored by transfection of pEGFPmass spectrometry (MALDI-TOF-MS) on a Bruker Biflex III instru-C1 (Clontech) and was routinely found to be 90%-95%. Transient ment (Bruker) using standard settings for peptide mass fingerprinttransfections of siRNA were performed using lipofectamine PLUS ing (PMF). The identity of Smad7 was confirmed by PMF using (Invitrogen). The p300 siRNA (directed against nucleotides 4751-ProFound. To identify acetylated lysine residues, the peptide mass 4773 in human p300; accession number U01877) and the control list was imported into GPMAW (version 4.22, Lighthouse Data) where GL2 siRNA (directed against firefly luciferase) were used according the sequence of Smad7 was scanned for the addition of 42 Da on to the manufacturer's recommendations (Dharmacon Research). a lysine residue. A similar search for acetylated lysines was also done in ProFound, long form. 
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